EPRX
Eupraxia Pharmaceuticals Inc

119
Loading...
Loading...
News
all
press releases
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE...
PR Newswire·7mo ago
News Placeholder
More News
News Placeholder
Eupraxia Pharmaceuticals Announces CFO Succession
Eupraxia Pharmaceuticals Announces CFO Succession Eupraxia Pharmaceuticals Announces CFO Succession PR Newswire VICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is retiring, and former CFO Alex Rothwell...
PR Newswire·7mo ago
News Placeholder
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months Eupraxia's DiffuSphere Technology Demonstrates Targeted...
PR Newswire·10mo ago
News Placeholder
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual...
PR Newswire·10mo ago
News Placeholder
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed', on November 15, 2024 Eupraxia...
PR Newswire·10mo ago
News Placeholder
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eupraxia Pharmaceuticals Announces Positive Data...
PR Newswire·10mo ago
News Placeholder
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of...
PR Newswire·11mo ago
News Placeholder
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual...
PR Newswire·11mo ago
News Placeholder
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals...
PR Newswire·11mo ago
News Placeholder
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC, Oct. 10...
PR Newswire·11mo ago

Latest EPRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.